The bill expands and standardizes veterans’ access to FDA‑approved non‑opioid postoperative pain treatments—improving safety and consistency—but does so with likely higher VA spending, restricted use of a toxic‑exposure fund that may shift costs away from other veteran care, and tight implementation deadlines that could strain VA operations.
Veterans undergoing surgery will get faster access to FDA‑approved non‑opioid postoperative pain treatments through VA formulary inclusion, expanding pain‑management options and likely reducing reliance on opioids (lowering addiction/overdose risks).
VA hospitals and clinicians will have a standardized set of approved non‑opioid postoperative pain products across facilities, simplifying prescribing and procurement and improving consistency of postoperative care.
Taxpayers and the VA medical system may face higher drug spending or procurement costs because the bill mandates formulary inclusion on a timeline, increasing short‑term VA expenditures.
Veterans who rely on toxic‑exposure care could be harmed if costs are shifted away from the Cost of War Toxic Exposures Fund (which the bill prohibits using for implementation), reducing resources available for those programs.
The 90‑day implementation deadline and other rapid timelines may strain VA administrative capacity (Secretary of Veterans Affairs, VA staff, hospitals), risking rushed evaluations or procurement decisions and implementation problems.
Based on analysis of 2 sections of legislative text.
Requires VA to add FDA-authorized non-opioid postoperative/regional analgesic drugs and biologics to its National Formulary and standardization list within set timelines.
Official title: To amend title 38, United States Code, to ensure that the Secretary of Veterans Affairs furnishes certain non-opioid pain medications to veterans, and for other purposes.
Introduced July 17, 2025 by Greg Landsman · Last progress July 17, 2025
Requires the Department of Veterans Affairs to add FDA-authorized non-opioid pain management drugs and biological products to the VA National Formulary and the VA drug standardization list. It sets timelines for implementation and prohibits using the Cost of War Toxic Exposures Fund to carry out the change. The law defines covered non-opioid products as those that reduce postoperative pain or produce postsurgical or regional analgesia without acting on opioid receptors, and requires the VA to add eligible products to its formulary within specified timeframes: immediate implementation responsibilities within 90 days and inclusion in the National Formulary within one year after the product becomes eligible for certain Medicare payment rules or comparable regulations.